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A B S T R A C T
Background: Increased levels of uric acid (UA) have been associated with cardiovascular disease. This
association is generally stronger in women than men. However, gender differences in the prognostic
value of UA in patients with acute coronary syndrome (ACS) are unknown. We investigated gender
differences in the relationship between UA level and the prognosis in patients with ACS.
Method: This was an observational analysis of patients with ACS undergoing percutaneous coronary
intervention enrolled in the Ibaraki Cardiac Assessment Study (ICAS) registry. We analyzed 1380 patients
(330 women, 1050 men) with ACS who had information on UA. We assessed the association between UA
and the incidence of major cardiovascular adverse events (MACE), deﬁned as all-cause death, congestive
heart failure, reinfarction, and stroke. Patients were divided according to gender-speciﬁc UA quartile.
Results: The mean UA level in women was signiﬁcantly lower than that in men (4.9 mg/dl vs 5.9 mg/dl,
p < 0.001). After a median duration of follow-up period of 437 days (interquartile range 222–801 days),
MACE had occurred in 186 (13%) patients [56 (17%) events in women; 130 (12%) events in men]. Kaplan-
Meier analysis for MACE-free survival demonstrated that a higher quartile of UA was associated with
MACE in both women and men (p < 0.001, p = 0.002, respectively). Multivariate Cox regression analysis
revealed that the highest quartile of UA, as compared with the lowest quartile of UA, was an independent
predictor of MACE in women [hazard ratio (HR), 2.84; 95% CI, 1.19–6.77; p = 0.018] but not in men (HR,
1.32; 95% CI, 0.66–2.64; p = 0.422).
Conclusions: An increased level of UA was associated with MACE more strongly in women than in men
with ACS. These results suggest that there are gender differences in the association of UA level with the
prognosis in patients with ACS.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Many epidemiological studies have suggested that elevation of
the serum uric acid (UA) level is a risk factor for hypertension,
obesity, dyslipidemia, and diabetes mellitus, all of which are
also associated with an increased risk for cardiovascular disease
[1–5]. Hyperuricemia is common among patients with heart* Corresponding author at: Cardiovascular Division, Faculty of Medicine,
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0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsfailure and is associated with poor outcome [6]. UA is an end
product of purine metabolism, and an increase in its concentration
may reﬂect increased xanthine oxidase pathway activity, which
relates to free radicals that result in increased cytokine production,
cell apoptosis, and endothelial dysfunction [7,8]. UA plays a role
not only as risk factors for cardiovascular risk but also as
scavengers against oxidative stress [7]. There is a gender difference
in UA level; women usually have a lower UA level than men. The
association between serum UA and cardiovascular events in the
general population is reported to be stronger in women than in
men [9]. Other studies have demonstrated that serum UA is more
closely related with metabolic syndrome in women than in men
[10]. In addition, gender differences also exist in the mortality rate reserved.
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myocardial infarction is worse in women than in men [11,12]. Thus
gender differences in cardiovascular risk factors and mortality are
being increasingly recognized and have become an important
issue. Use of various biomarkers such as renal function, natriuretic
peptide, and cardiac troponin has helped to improve risk
prediction in patients with acute coronary syndrome (ACS), but
risk prediction in patients with ACS remains suboptimal
[13–16]. Some studies have shown that UA is an independent
predictor of mortality in patients with myocardial infarction
[17]. Although there are gender differences in relation to UA level,
no study has been conducted to access the association of gender
differences with the prognostic value of UA in patients with ACS.
We undertook this study to investigate whether UA level predicts
clinical outcome in a large cohort of patients with ACS who
underwent percutaneous coronary intervention (PCI).
Materials and methods
Study population
We pooled data from patients enrolled in the Ibaraki Cardiac
Assessment Study (ICAS) registry, a multicenter registry involving
12 hospitals in Ibaraki Prefecture, Japan. All traceable personal
identiﬁers were removed from the datasets before analysis to
protect patient conﬁdentiality. Written informed consent was
obtained from all patients, and data collection for this study was
approved by each institution’s review board. We enrolled
1828 consecutive patients with ACS who underwent PCI from
April 2007 to June 2012. Among them, 448 patients who were
missing UA values were excluded. Thus, the study group comprised
1380 patients. In each participant, blood was withdrawn before
coronary angiography. Serum UA was determined by the uricase-
peroxidase method in each participating hospital. Because serum
UA level differs substantially between the sexes, results were
analyzed separately. Patients were divided according to gender-
speciﬁc UA quartile.
ACS was deﬁned as ST-elevation myocardial infarction, non-ST-
elevation myocardial infarction, or unstable angina. The diagnosis of
ACS was based on the universal deﬁnition of myocardial infarction
[18]. Coronary artery disease was diagnosed based on the presence
of >75% lumen obstruction of at least one of the three major
coronary arteries. Hypertension was deﬁned as the presence of
current treatment with antihypertensive drugs or otherwise as a
systolic blood pressure of >140 mmHg and/or diastolic blood
pressure of >90 mmHg. Dyslipidemia was deﬁned as current
treatment with cholesterol-lowering medications or a low-density
lipoprotein (LDL) cholesterol value of >140 mg/dl and/or a high-
density lipoprotein cholesterol value of <40 mg/dl. Diabetes
mellitus was deﬁned as a fasting glucose concentration of
>126 mg/dl or treatment with oral hypoglycemic agents or insulin.
The estimated glomerular ﬁltration rate (eGFR) was calculated with
the following equation: eGFR = 194  (serum creatinine)1.094
(age)0.287 (0.739 if the patient is female) [19].
Coronary angiography and PCI procedure
PCI was performed according to standard techniques. All
patients received treatment with aspirin (100 mg/day) and
clopidogrel (75 mg/day following a 300 mg loading dose) or
ticlopidine (200 mg/day). A glycoprotein IIb/IIIa receptor inhibitor
is not yet available in Japan. Operators selected interventional
devices and performed PCI through either the radial, brachial, or
femoral artery using 6–7 French catheters. Heparin was given
intravenously before starting the procedure. The standard of care
at discharge for all patients treated with stents was to prescribeclopidogrel for at least 1 year. Aspirin was continued indeﬁnitely
unless complications occurred. Informed consent was obtained
from all patients, and approval for this study was granted by each
institution’s ethics committee. All adverse events were conﬁrmed
by reviewing the medical records of the patients followed at each
institution.
Endpoints and deﬁnitions
The primary endpoint of this study was major adverse
cardiovascular events (MACE) deﬁned as death from any cause,
congestive heart failure, myocardial infarction, or stroke. Conges-
tive heart failure was deﬁned as admission to hospital for
worsening heart failure requiring intravenous drug treatment.
Stroke was deﬁned as cerebral infarction, intracranial hemorrhage,
or subarachnoid hemorrhage diagnosed by computed tomography
or magnetic resonance imaging.
Statistical analysis
Continuous variables are expressed as mean  SD, medians
(interquartile range), and categorical variables as numbers and
percentages. Comparisons between quartiles were made by analysis
of variance test for continuous variables and the Pearson chi-square
test for categorical variables. Comparisons between the enrolled
patients and the patients with missing UA values were analyzed by
the Pearson chi-square statistics for categorical variables and
unpaired t test or Mann-Whitney U tests for continuous variables
according to the distribution. Survival analysis was performed by
applying the Kaplan-Meier method and log-rank test. Univariate and
multivariate Cox proportional hazards models were used to assess the
association between UA quartile and MACE. Potential confounding
factors with regard to baseline characteristics were included in
multivariate analysis. The covariates for the multivariate analysis
included UA, age, body mass index, diabetes mellitus, left ventricular
ejection fraction, eGFR < 60 mL/min/1.73 m2, history of heart failure,
ST-elevation myocardial infarction, hyperlipidemia, and hyperten-
sion. All statistical analyses were performed with EZR (Saitama
Medical Center, Jichi Medical University, Tochigi, Japan), which is a
graphical user interface for the R statistical analysis program (The R
Foundation for Statistical Computing, version 2.13.0) [20]. A two-
tailed p-value of <0.05 was considered to indicate statistical
signiﬁcance.
Results
Clinical and procedural characteristics
Baseline demographic, clinical, and angiographic characteris-
tics of both women and men stratiﬁed by UA quartile are shown in
Tables 1 and 2. The subjects included 330 women (24%; age,
72.1  10.6 years) and 1050 men (76%; age, 64.5  11.7 years). Of
particular note is the different age distribution by UA quartile
between the women and men. The quartile of UA increased with age
only in women (p < 0.001) but not in men (p = 0.092). In contrast, the
quartile of UA increased with higher body mass index only in men
(p = 0.001) and not in women (p = 0.535). In women, a higher quartile
of UA was associated with decreased LDL cholesterol (p < 0.001).
Among both women and men, a higher quartile of UA level was
associated with increasing blood urea nitrogen (BUN) and eGFR
(p < 0.001, both). Women with history of heart failure, but not
men, had higher UA level than those without history of heart
failure (women, p < 0.001; men, p = 0.09). There were also gender
differences in medication on admission. There was no signiﬁcant
difference in the types of medication used in men. On the other
hand, angiotensin II receptor blocker was used more frequently in
Table 1
Baseline characteristics in women.
Quartile1
n = 81
Quartile2
n = 82
Quartile3
n = 74
Quartile4
n = 93
p-value
Uric acid (mg/dl) <3.9 3.9–4.9 4.9–6.2 >6.2
Age, years 68.5  10.8 70.8  10.9 73.0  9.9 76.7  9.0 <0.001
BMI (kg/m2) 23.2  4.1 23.9  3.7 23.1  3.8 23.8  4.4 0.535
SBP (mmHg) 137.1  26.3 133.8  26.1 138.2  31.0 126.0  32.8 0.045
DBP (mmHg) 74.5  17.0 73.6  15.7 73.7  17.4 68.9  18.8 0.168
HR (bpm) 80.1  17.6 76.7  16.5 78.7  19.4 79.0  23.4 0.732
BUN (mg/dl) 15.1  6.2 16.5  7.0 23.5  17.7 24.4  11.8 <0.001
eGFR (mL/min/1.73 m2) 79.8  29.2 71.1  25.0 58.1  25.1 45.4  21.5 <0.001
CRP (mg/dl) 1.42  3.25 1.27  3.22 1.61  3.94 1.45  3.48 0.948
Hb (g/dl) 12.7  1.9 12.5  1.3 12.1  2.1 11.9  2.3 0.057
Glucose (mg/dl) 192.5  90.8 155.1  64.8 184.5  117.5 179.8  86.3 0.069
WBC (103/mg) 8945  3141 7963  2570 9150  4579 9346  4147 0.082
STEMI 47 (58.0) 53 (64.6) 47 (63.5) 40 (52.6) 0.407
EF (%) 56.4  11.1 56.8  12.7 54.7  12.2 52.2  13.9 0.124
HDL cholesterol (mg/dl) 52.0  12.2 51.1  12.6 54.4  32.3 45.5  14.6 0.063
Triglycerides (mg/dl) 119.8  80.9 112.4  71.1 122.3  99.0 129.2  142.9 0.785
LDL cholesterol (mg/dl) 138.2  39.9 119.3  36.5 117.6  29.9 106.5  32.3 <0.001
Medication on admission
Allopurinolol 3 (3.7) 1 (1.2) 1 (1.4) 4 (5.3) 0.398
ACE-I or ARB 46 (56.8) 51 (62.2) 39 (52.7) 54 (71.1) 0.110
Beta blockers 36 (44.4) 40 (48.8) 25 (33.8) 23 (30.3) 0.057
Statin 58 (71.6) 62 (75.6) 48 (64.9) 40 (52.6) 0.015
History of HT 51 (63.0) 66 (80.5) 51 (68.9) 57 (75.0) 0.076
History of DM 33 (40.7) 27 (32.9) 33 (44.6) 23 (30.3) 0.225
History of HF 0 (0.0) 1 (1.2) 0 (0.0) 10 (13.2) <0.001
History of MI 7 (8.6) 8 (9.8) 8 (10.8) 13 (17.1) 0.394
History of PCI 15 (18.5) 11 (13.4) 9 (12.2) 14 (18.4) 0.605
History of CABG 0 (0.0) 2 (2.4) 1 (1.4) 3 (3.9) 0.291
History of stroke 4 (4.9) 3 (3.7) 6 (8.1) 10 (13.2) 0.120
Multivessel disease (%) 22 (28.6) 17 (23.3) 19 (27.5) 28 (40.6) 0.147
Values are expressed as the mean  SD, or n (%).
ACE-I, angiotensin-converting inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; BUN, blood urea nitrogen; CABG, coronary artery bypass graft; CRP, C-
reactive protein; DBP, diastolic blood pressure; DM, diabetes mellitus; EF, ejection fraction; eGFR, estimated glomerular ﬁltration rate; Hb, hemoglobin; HDL, high-density
lipoprotein; HF, heart failure; HL, hyperlipidemia; HR, heart rate; HT, hypertension; LDL, low-density lipoprotein; MI, myocardial infarction; PCI, percutaneous coronary
intervention; SBP, systolic blood pressure; STEMI, ST-elevation myocardial infarction; WBC, white blood cell count.
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used less frequently in women with a higher quartile of UA
(p = 0.015).
We evaluated the possible selection bias by comparing the
patient’s backgrounds between the enrolled patients (n = 1380)
and patients with missing UA value (n = 488). As shown in
Supplemental Table 1, there were no signiﬁcant differences
between the enrolled patients and patients with missing UA
value, except for the history of PCI and multivessel disease.
Supplementary material related to this article can be found, in
the online version, at doi:10.1016/j.jjcc.2015.05.009.
UA levels and clinical events
The mean UA level in women was signiﬁcantly lower than that
in men (4.9 mg/dl vs 5.9 mg/dl, p < 0.001) (Figs. 1 and 2). After a
median duration of follow-up of 437 days (interquartile range
222–801 days) and 2081 person-years (interquartile range
791–7755 person-years), 186 (13%; 8.93 per 100 person-years)
patients experienced MACE [56 (17%; 12.5 per 100 person-years)
events in women and 130 (12%; 8.24 per 100 person-years) events
in men], all-cause death occurred in 98 (7%; 4.71 per 100 person-
years) patients [31 (9%; 6.91 per 100 person-years) events in
women; 67 (6%; 4.24 per 100 person-years) events in men]. In both
genders, all-cause death (women, p = 0.002; men, p = 0.043) and
incidence of MACE (women, p < 0.001; men, p = 0.003) were
higher in patients with a higher quartile of UA. Cardiac death and
occurrence of heart failure were signiﬁcantly higher only in
women with a higher quartile of UA (p < 0.001 and p = 0.041,
respectively), but not in men (p = 0.055 and p = 0.329, respectively)(Table 3). Kaplan-Meier analysis for MACE-free survival showed
that a higher UA quartile was associated with MACE in all patients
(p < 0.001) (Fig. 3). Kaplan-Meier curves for MACE stratiﬁed by
women and men showed that a higher quartile was associated
with MACE in both women and men (p < 0.001, p = 0.002,
respectively) (Fig. 4).
Predictors of clinical events according to multivariate analysis
In univariate analysis, the highest UA quartile (>6.2 mg/dl in
women; >6.9 mg/dl in men), as compared with the lowest UA
quartile (<3.9 mg/dl in women; <4.9 mg/dl in men), was
associated with MACE in both women [hazard ratio (HR), 4.60;
95% conﬁdence interval (CI), 2.09–10.12; p < 0.001] and men
(HR, 1.90; 95% CI, 1.15–3.13; p = 0.011) (Table 4). However, in
multivariate analysis, the highest quartile of UA was independent-
ly associated with MACE only in the women (HR, 2.84; 95% CI,
1.19–6.77; p = 0.018) but not in the men (HR, 1.32; 95% CI,
0.66–2.64; p = 0.422).
Discussion
In this study with subjects from a multicenter registry of
patients with ACS undergoing PCI, the impact of UA levels on MACE
remained independent in women, but not in men, even after
adjustment for traditional cardiovascular risk factors. The effect of
gender differences in the role of UA on the long-term prognosis of
patients with ACS has not previously been fully explored. To our
knowledge, this is the ﬁrst study to elucidate gender differences in
UA for the prognosis of patients with ACS.
Table 2
Baseline characteristics in men.
Quartile1
n = 265
Quartile2
n = 274
Quartile3
n = 264
Quartile4
n = 247
p-value
Uric acid (mg/dl) <4.9 4.9–5.9 5.9–6.9 >6.9
Age, years 64.9  10.5 65.6  11.9 64.4  11.0 63.1  13.1 0.092
BMI (kg/m2) 23.5  3.6 24.2  3.7 24.6  4.0 26.1  13.0 0.001
SBP (mmHg) 135.2  26.8 136.0  27.3 134.6  25.3 134.8  30.8 0.937
DBP (mmHg) 79.8  16.2 79.2  16.2 79.9  18.0 79.0  18.7 0.928
HR (bpm) 76.7  18.9 74.6  17.8 75.6  18.4 81.1  21.6 0.001
BUN (mg/dl) 15.1  4.6 16.1  6.4 18.7  16.1 21.6  13.5 <0.001
eGFR (mL/min/1.73 m2) 76.4  22.9 73.2  20.8 65.8  20.5 60.1  49.8 <0.001
CRP (mg/dl) 1.14  2.73 0.93  2.59 0.97  3.18 1.33  3.43 0.426
Hb (g/dl) 14.3  1.7 14.2  1.7 14.3  1.8 13.9  2.2 0.044
Glucose (mg/dl) 179.4  92.1 157.3  72.1 161.9  83.1 176.7  88.7 0.007
WBC (103/mg) 9084  3142 9136  3260 9171  3223 10,271  3937 <0.001
STEMI 150 (56.6) 152 (55.5) 150 (56.8) 147 (59.5) 0.822
EF (%) 56.3  12.6 56.5  11.5 55.2  12.0 54.9  12.9 0.416
HDL cholesterol (mg/dl) 48.5  13.7 46.6  11.3 46.5  13.0 44.0  12.2 0.002
Triglycerides (mg/dl) 118.5  92.7 135.0  133.0 143.6  131.2 174.8  203.8 <0.001
LDL cholesterol (mg/dl) 117.7  32.1 117.7  35.8 122.7  36.6 119.1  40.6 0.387
Medication on admission
Allopurinolol 6 (2.3) 9 (3.3) 11 (4.2) 14 (5.7) 0.233
ACE-I or ARB 166 (62.6) 167 (60.9) 177 (67.0) 148 (59.9) 0.344
Beta blockers 117 (44.2) 117 (42.7) 120 (45.5) 117 (47.4) 0.744
Statin 186 (70.2) 201 (73.4) 196 (74.2) 173 (74.2) 0.611
History of HT 154 (58.1) 165 (60.2) 175 (66.3) 151 (61.1) 0.255
History of DM 110 (41.5) 89 (32.5) 82 (31.1) 80 (32.4) 0.046
History of HF 4 (1.5) 4 (1.5) 4 (1.5) 11 (4.5) 0.090
History of MI 35 (13.2) 42 (15.3) 43 (16.3) 37 (15.0) 0.793
History of PCI 43 (16.2) 58 (21.2) 51 (19.3) 42 (17.0) 0.447
History of CABG 6 (2.3) 13 (4.7) 4 (1.5) 5 (2.0) 0.126
History of stroke 17 (6.4) 19 (6.9) 24 (9.1) 20 (8.1) 0.655
Multivessel disease (%) 74 (30.3) 67 (26.5) 77 (31.6) 67 (30.5) 0.618
ACE-I, angiotensin-converting inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; BUN, blood urea nitrogen; CABG, coronary artery bypass graft; CRP,
C-reactive protein; DBP, diastolic blood pressure; DM, diabetes mellitus; EF, ejection fraction; eGFR, estimated glomerular ﬁltration rate; Hb, hemoglobin; HDL, high-
density lipoprotein; HF, heart failure; HL, hyperlipidemia; HR, heart rate; HT, hypertension; LDL, low-density lipoprotein; MI, myocardial infarction; PCI, percutaneous
coronary intervention; SBP, systolic blood pressure; STEMI, ST-elevation myocardial infarction; WBC, white blood cell count.
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A number of studies have suggested that the elevation of UA in
patients with cardiovascular disease could simply be a result of the
common presence of high-risk factors such as reduced eGFR,
history of heart failure, and hypertension, all of which are
associated with worse prognosis [6,7]. However, after adjustment
for these risk factors in our multivariate model, we still found that a
highest quartile of UA was an independent predictor of MACE in
female patients with ACS not in male patients. In the general
population, UA is an independent risk factor for hypertension,Fig. 1. Histogram of uric acid concentrations in women.dyslipidemia, metabolic syndrome, and renal disease
[1,3,10,21]. In patients with severe coronary artery disease, an
elevated UA level was a strong independent predictor of adverse
outcome and mortality [22]. This prognostic value of UA was also
shown in patients with ACS. Kojima et al. showed that the
combination of Killip’s class and UA was signiﬁcantly associated
with mortality in patients with acute myocardial infarction
[23]. Kaya et al. showed that a high UA level on admission was
independently associated with MACE in patients with ST-elevation
myocardial infarction who undergo PCI [17]. The meta-analysis by
Trkulja et al. reported a signiﬁcant association between UA levelFig. 2. Histogram of uric acid concentrations in men.
Table 3
Proportion of event occurrence in the patients according to gender and quartile of uric acid.
Q1 <3.9 mg/dl
n = 81; 115 person-years
Q2 3.9–4.9 mg/dl
n = 82; 137 person-years
Q3 4.9–6.2 mg/dl
n = 74; 103 person-years
Q4 >6.2 mg/dl
n = 76; 93 person-years
p-value
Women
All death 3 (2.60) 4 (2.91) 9 (8.73) 15 (16.10) 0.002
Cardiac death 2 (1.73) 1 (0.72) 6 (0.05) 10 (10.75) <0.001
Heart failure 4 (3.47) 5 (3.64) 3 (2.91) 12 (12.90) 0.041
Stroke 2 (1.73) 1 (0.72) 0 (0.00) 5 (5.37) 0.053
Myocardial infarction 2 (1.73) 2 (1.45) 0 (0.00) 2 (2.15) 0.613
MACE 8 (6.95) 10 (7.29) 10 (9.70) 28 (31.00) <0.001
Q1 <4.9 mg/dl
n = 265; 406 person-years
Q2 4.9–5.9 mg/dl
n = 274; 421 person-years
Q3 5.9–6.9 mg/dl
n = 264; 414 person-years
Q4 >6.9 mg/dl
n = 247; 336 person-years
p-value
Men
All death 16 (3.94) 11 (2.61) 15 (3.62) 25 (7.44) 0.043
Cardiac death 7 (1.72) 5 (1.18) 5 (1.20) 14 (4.16) 0.055
Heart failure 7 (1.72) 8 (1.90) 14 (3.38) 11 (3.27) 0.329
Stroke 4 (0.98) 5 (1.18) 8 (1.93) 8 (2.38) 0.491
Myocardial infarction 3 (0.73) 2 (0.47) 3 (0.72) 5 (1.48) 0.627
MACE 27 (6.65) 22 (5.22) 36 (8.69) 45 (13.39) 0.003
Values are expressed as the n (per 100 person-years).
MACE, major adverse cardiac and cerebrovascular event.
Fig. 3. Kaplan-Meier curves for major adverse cardiovascular event (MACE)-free
survival according to quartile of uric acid (UA) in all patients.
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infarction [24]. Some studies have demonstrated that there is a
signiﬁcant relationship between UA level and post-primary PCI
myocardial perfusion grade [22,25]. UA has been shown to be an
indicator of antioxidant activity in serum [26]. Hyperuricemia hasFig. 4. Kaplan-Meier curves for major adverse cardiovascular event (MACE)-been suggested to reﬂect raised xanthine oxidase activity in
patients with heart failure [27]. The xanthine oxidase enzyme
system is an important source of oxygen free radicals [28]. High UA
levels not only contribute to oxygen free radical generation but
also decrease the amount of nitric oxide in vascular endothelial
cells, which in turn inhibits vasodilatation [17]. The subsequent
generation of oxygen free radicals is one of the underlying causes
of impaired coronary ﬂow after primary PCI [29]. Endothelial-
derived nitric oxide, a potent vasodilator, plays an important role
in the regulation of coronary blood ﬂow [30]. Allopurinol has been
found to improve endothelial function in type 2 diabetes,
hyperuricemic patients with chronic heart failure, and heavy
smokers [31]. Further studies will be needed to determine whether
allopurinol affects the prognosis of ACS patients with an elevated
UA.
Relationship between UA and gender
Several previous studies have demonstrated that UA level
regarding development of hypertension or renal disease was
signiﬁcantly higher in women than in men [32,33]. There also have
been gender differences in the association between UA level and
atrial ﬁbrillation prevalence [34]. Freedman et al. demonstrated afree survival according to quartile of UA stratiﬁed by women and men.
Table 4
Cox regression analysis for MACE.
Non-adjusted model Adjusted model
HR (95% CI) p-value HR (95% CI) p-value
Women
Quartile1 (<3.9 mg/dl) Reference Reference
Quartile2 (3.9–4.9 mg/dl) 1.24 (0.49–3.16) 0.639 0.86 (0.29–2.51) 0.783
Quartile3 (4.9–6.2 mg/dl) 1.58 (0.62–4.02) 0.331 0.61 (0.18–2.06) 0.430
Quartile4 (>6.2 mg/dl) 4.60 (2.09–10.12) <0.001 2.84 (1.19–6.77) 0.018
Men
Quartile1 (<4.9 mg/dl) Reference Reference
Quartile2 (4.9–5.9 mg/dl) 0.80 (0.45–1.42) 0.456 0.69 (0.32–1.45) 0.331
Quartile3 (5.9–6.9 mg/dl) 1.50 (0.90–2.48) 0.114 1.05 (0.54–2.02) 0.874
Quartile4 (>6.9 mg/dl) 1.90 (1.15–3.13) 0.011 1.32 (0.66–2.64) 0.422
HR in adjusted model was adjusted for age, body mass index, diabetes mellitus, ejection fraction, estimated glomerular ﬁltration rate < 60 mL/min/1.73 m2, history of
heart failure, ST-elevation myocardial infarction, hyperlipidemia, and hypertension.
HR, hazard ratio; CI, conﬁdence interval.
M. Kawabe et al. / Journal of Cardiology 67 (2016) 170–176 175stronger association between increased UA level and cardiovascu-
lar mortality among women than men in healthy subjects
[5]. Meta-analysis showed that an association between hyperuri-
cemia and cardiovascular mortality was signiﬁcant in women but
not in men [35]. Few studies have addressed the association
between UA levels and gender differences in the prognosis of
patients with ACS. In patients admitted for elective coronary
angiography, high UA levels were linearly related to coronary
artery disease severity in women, but UA was eliminated from
multivariate model because the association of UA to coronary
artery disease largely reﬂects predominance of metabolic risk
factors such as hyperinsulinemia, advanced age, hypertension, and
dyslipidemia [36]. The present study demonstrates that UA has
gender differences on the prognosis in patients with ACS because
the association remained even after adjustment for comorbidities
in women, but not in men. Postmenopausal women had a higher
UA level than premenopausal women [7]. The changing UA level in
postmenopausal women suggests that there is an interaction with
sex hormones [9]. Some studies have demonstrated a strong
association between UA level in healthy populations and
cardiovascular mortality, even after adjustment for menopausal
status [9,37]. Although increasing UA level after menopause might
inﬂuence outcomes, it remains a matter for further discussion. The
mechanisms that cause UA to be less related to MACE in men than
women remain uncertain and providing a potential explanation for
this ﬁnding would be rather speculative. However, one reason is
that men have another strong risk factor inﬂuencing the mortality
of patients with MACE rather than women. Among patients with
established coronary artery disease, lower BMI is an independent
predictor of mortality [38]. We found that BMI was increased with
quartile of UA only in men (Table 1). This trend would attenuate
the excess effect of elevated UA level.
Study limitations
Our study has several limitations. This was a nonrandomized,
retrospective, and observational study, and as with any observa-
tional study, it is possible that both unrecognized and recognized
confounding factors may inﬂuence the data despite adjustment for
these factors. There could be a selection bias in the present study as
shown in Supplemental Table 1. The study ﬁndings are based on a
single UA measurement. As a result, time-dependent changes in
UA concentration remain unaccounted for. Additional factors
that affect UA concentration, such as doses and types of diuretics
(e.g. loop diuretics, thiazide, and spironolactone) were also not
assessed. Because N-terminal pro B-type natriuretic peptide, brain
natriuretic peptide, and high-sensitivity troponin assays were notavailable for the majority of the patients in this study, we could not
adjust for these biomarkers. Finally, menopausal status and history
of gout are not available in this study.
Conclusions
In conclusion, among patients with ACS, an increased UA level
was associated with MACE in both women and men. The effect of
UA level on MACE remained independent even after adjustment for
the traditional cardiovascular risk factors in women but not in
men. These results suggest that there are gender differences in the
association of UA level with the prognosis in patients with ACS.
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